Intravitreous CytokinE Level in pAtient With retiNal Detachment (ICELAND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03318588|
Recruitment Status : Unknown
Verified October 2017 by Docteur Jean-Baptiste CONART, Central Hospital, Nancy, France.
Recruitment status was: Not yet recruiting
First Posted : October 24, 2017
Last Update Posted : October 24, 2017
Photoreceptor apoptosis is the basis for permanent visual loss in a number of retinal disorders including age-related macular degeneration (AMD) and retinal detachment (RD). Thus, despite tremendous advances in vitreoretinal surgery and management of rhegmatogenous RD leading to a primary reattachment rate over 95%, some patients show poor visual recovery because of photoreceptor apoptosis.
Physiologically, microglial cells (resident macrophages) are present only in the inner retina. The subretinal space, located between the retinal pigment epithelium (RPE) and the photoreceptor outer segments (POS), is devoid of all mononuclear phagocytes and form a zone of immune privilege. In AMD, several studies showed a strong association between subretinal mononuclear phagocytes infiltration and advanced forms of AMD. Experimental work in mice suggest that this infiltration plays an important role in the pathogenesis of this condition by producing inflammatory cytokines.
RD-induced photoreceptor apoptosis might result from similar mechanisms. The aim of this study is to determine the cytokine profile in vitreous samples from patients with RD and to compare it with those from control patients with macular hole.
|Condition or disease||Intervention/treatment|
|Retinal Detachment||Procedure: Vitrectomy|
|Study Type :||Observational|
|Estimated Enrollment :||74 participants|
|Official Title:||Intravitreous CytokinE Level in pAtient With retiNal Detachment|
|Estimated Study Start Date :||November 2017|
|Estimated Primary Completion Date :||May 2019|
|Estimated Study Completion Date :||November 2019|
Patients undergoing vitrectomy for primary retinal detachment
Pars plana vitrectomy
Patients undergoing vitrectomy for idiopathic macular hole
Pars plana vitrectomy
- Intravitreous cytokine levels [ Time Frame: up to one month after surgery ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03318588
|Contact: Jean-Baptiste CONART, MD||+(33)firstname.lastname@example.org|
|Vandœuvre-lès-Nancy, France, 54500|
|Principal Investigator:||Jean-Baptiste CONART, MD||Brabois Hospital, Department of Ophthalmology|